Optic nerve head: an initial site of relapse in acute lymphoblastic leukaemia

Vipin Rana,Deeksha Katoch

DOI: https://doi.org/10.1038/s41433-024-03452-z

IF: 4.4563

2024-11-28

Eye

Abstract:Eye, Published online: 27 November 2024; doi:10.1038/s41433-024-03452-z Optic nerve head: an initial site of relapse in acute lymphoblastic leukaemia

ophthalmology

What problem does this paper attempt to address?

Isolated Optic Nerve Relapse in a Pediatric Patient With T-Cell Lymphoblastic Leukemia: A Brief Report

Rakefet Shenkar,Samir B Kahwash,Diana P Rodriguez,Rolla Abu Arja,Suzanne M Reed,Hemalatha G Rangarajan

DOI: https://doi.org/10.1097/MPH.0000000000002893

2024-08-01

Abstract:Isolated optic nerve (ON) relapse is a rare occurrence in lymphoblastic leukemia (LBL). A 10-year-old boy with T-LBL presented 8 months after diagnosis with blurred vision and thickening of right ON on magnetic resonance imaging consistent with relapse. Cerebrospinal fluid and bone marrow were negative for leukemia. He received reinduction chemotherapy (including nelarabine and craniospinal radiation) followed by a myeloablative matched sibling donor bone marrow transplant. He remains in remission 2 years post-transplant with normal vision. We also review the literature for reports of isolated ON relapse in patients with LBL. Our patient's clinical course demonstrates that disease control can be achieved with early detection of ON relapse before disease progression.
Lymphopenia During Routine Follow-Up May Predict Relapse in Patients with Extranodal NK/T Cell Lymphoma

Liang Wang,Jing-hua Wang,Zhi-jun Wu-Xiao,Zhong-jun Xia,Hui-qiang Huang,Yue Lu

DOI: https://doi.org/10.1007/s13277-014-2776-1

2014-01-01

Tumor Biology

Abstract:Recently, absolute lymphocyte count (ALC) at diagnosis, as a surrogate marker of host immunity, has been reported to be a prognostic factor for clinical outcomes in extranodal NK/T cell lymphoma (ENKTL). In this retrospective study, we set out to investigate whether ALC at the time of confirmed relapse or at last follow-up is a marker for relapse after chemoradiotherapy in 84 patients with stage I/II ENKTL. Receiver operating characteristics (ROC) curve and area under the curve (AUC) analysis showed that ALC at follow-up was a significant marker for relapse (AUC = 0.883, P < 0.001). Using 1.215 × 10 9 /L as the optimal cutoff value of ALC, 44 patients (52.4 %) were in lower ALC group and 40 patients (47.6 %) were in higher ALC group. The sensitivity and specificity for ALC at the time of confirmed relapse or at last follow-up was 94.1 and 76.0 %, respectively. The relative risk of relapse with an ALC < 1.215 × 10 9 /L was 14.5. The positive predictive value with an ALC < 1.215 × 10 9 /L was 72.7 %, and the negative predictive value with an ALC ≥ 1.215 × 10 9 /L was 95.0 %. The 4-year cumulative incidence rate for an ALC < 1.215 × 10 9 /L was 73.2 % compared with 3.2 % for an ALC ≥ 1.215 × 10 9 /L ( P < 0.001). In a multivariate regression analysis, ALC at the time of confirmed relapse or last follow-up remained to be a significant factor for relapse ( P < 0.001). In conclusion, lymphopenia observed during routine follow-up can predict relapse in patients with ENKTL, which needs further validation in prospective trials.
Leukaemic Optic Neuropathy in a Patient with Treated Acute Lymphoblastic Leukaemia: Optical Coherence Tomography as an Aid to Diagnosis

James Richardson-May,Abdi M Musa,Priyadarshini Suresh,Jan J Sniatecki,Radhika Krishnan

DOI: https://doi.org/10.1080/01658107.2024.2313579

2024-02-08

Abstract:Leukaemic optic neuropathy is an uncommon cause of visual loss which represents a neuro-oncological emergency with the potential of irreversible blindness if untreated. It can be difficult to diagnose, often presenting with normal neuroradiological and cerebrospinal fluid findings. We present the case of a 26-year-old woman with T-cell acute lymphoblastic leukaemia with optic neuropathy secondary to leukaemic infiltration, who demonstrated features on optical coherence tomography that aided the diagnosis of this condition. This included the presence of numerous, small, hyperreflective opacities erupting from the optic nerve head, which improved following treatment with radiotherapy and chemotherapy, and later recurred when the condition relapsed. This finding may help clinicians differentiate between other causes of optic neuropathy as well as assessing response to treatment and monitoring for recurrence.
Bilateral optic nerve infiltration and leukemic retinopathy as initial signs of leukemia relapse with central nervous system involvement in an adult: a case report

Yisai Wang,Ling Zhu,Hongtao Wang,Zhen Li,Ruomeng Bai,Qinghua Wei,Lin Huang,Ying Xu,Songguo Li,Hui Chen

DOI: https://doi.org/10.1186/s12886-024-03486-7

IF: 2.086

2024-05-31

BMC Ophthalmology

Abstract:We describe a case in which bilateral optic nerve infiltration and leukemic retinopathy were the initial signs of disease relapse in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + -ALL) with central nervous system (CNS) involvement.

ophthalmology
Leukemic occult infiltrative optic neuropathy presenting as optic neuritis: a case report

Fengsheng Xu,Yuan Wu,Yingzi Pan

DOI: https://doi.org/10.1186/s12886-024-03717-x

IF: 2.086

2024-10-12

BMC Ophthalmology

Abstract:Isolated ocular relapses of leukemia are rare and typically present as infiltrative lesions of the optic nerve. This report presents a case of an isolated ocular relapse of leukemia in a female patient, characterized by occult infiltrative optic neuropathy. Despite the absence of leukemic cell infiltration on MRI, a 33-year-old female patient presented with optic neuritis, which resolved after intrathecal administration of chemotherapeutic agents. However, due to her non-compliance with the treatment regimen, leukemia progressed to infiltrative optic neuropathy. She refused radiation therapy, and while intrathecal injections provided temporary stabilization, they were insufficient for sustained disease control. This case uniquely documents the extended progression of an isolated ocular relapse of leukemia, evolving from an occult infiltrative lesion initially presenting as optic neuritis to a more pronounced infiltrative lesion. It suggests that leukemic optic nerve infiltration can occur in patients with leukemia even in the absence of MRI-detectable abnormalities. Radiation therapy emerges as a critical modality in the management of infiltrative lesions of the optic nerve.

ophthalmology
A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings

J W Karesh,E J Goldman,K Reck,S E Kelman,E J Lee,C A Schiffer

DOI: https://doi.org/10.1200/JCO.1989.7.10.1528

Abstract:We report the results of a prospective 2-year study of the ocular manifestations of myeloid leukemia. Fifty-three patients underwent complete ophthalmic evaluation prior to the initiation of treatment as well as during the course of their disease. All ocular abnormalities were confined to the retina and optic nerve and were present in 34 patients, 30 of whom had either hemorrhages or cotton-wool spots alone or in combination. These findings were unrelated to age, sex, French-American-British (FAB) classification, and pretreatment leukocyte count or hematocrit. Patients with retinopathy had significantly lower platelet counts than those without retinopathy. Three patients had funduscopic evidence of optic nerve edema. None of these had clinical evidence of CNS leukemia. The presence of retinopathy was unrelated to therapeutic response. There was complete resolution of all ocular findings in those patients surviving the induction phase of therapy.
Unilateral isolated optic nerve infiltration combined with central retinal artery occlusion in a patient with acute myeloid leukemia

Chen Zhao,Duo Wei,Xuan Shi,Mingwei Zhao

DOI: https://doi.org/10.1016/j.ajoc.2022.101493

2022-01-01

American Journal of Ophthalmology Case Reports

Abstract:Purpose: To report a case of unilateral isolated optic nerve infiltration combined with central retinal artery occlusion in a patient with acute myeloid leukemia. Observations: A 28-year-old acute myeloid leukemia patient with systemic remission after hematopoietic stem cell transplantation presented with optic nerve infiltration combined with central retinal artery occlusion. Fundus examination showed diffuse papillary swelling with blurred margins and whitening macular with cherry-red spot. CBFβ-MYH11 fusion transcript analysis revealed central nervous system relapse of acute myeloid leukemia and optic nerve infiltration. Conclusions and importance: Isolated optic nerve infiltration combined with central retinal artery occlusion is an extremely rare presentation in acute myeloid leukemia. Even in the absence of cytological and radiographic evidence from cerebrospinal fluid, optic nerve infiltration should not be ignored.
Isolated Primary Central Nervous System Lymphoma of the Optic Nerve: A Case Report and Review of the Literature

Keertana Jain,Nicholas J Volpe,Karan Dixit

DOI: https://doi.org/10.1097/NRL.0000000000000581

2024-11-01

Abstract:Introduction: Optic nerve involvement in primary central nervous system lymphoma (PCNSL) has been reported only a few times in the literature, with generally dismal outcomes. We focused on an extremely rare presentation of PCNSL in an immunocompetent patient with isolated manifestations of the optic nerve. Case report: A 72-year-old man presented with subacute vision loss in his left eye and optic disc swelling. Initial magnetic resonance imaging (MRI) of the orbits revealed a T2 hyperintense signal with enhancement of the left prechiasmatic optic nerve, suggestive of optic neuritis. He experienced visual improvement after 6 weeks of prednisone. However, 2 months after steroid tapering, he presented with worsening left-eye vision loss and new right-eye vision loss with imaging showing a peripherally enhancing chiasm lesion. A biopsy of the left optic nerve confirmed diffuse large B-cell lymphoma and negative systemic imaging was consistent with PCNSL. He was treated with high-dose methotrexate, rituximab, procarbazine vincristine (R-MVP), and cytarabine (AraC) with some visual improvement in the right eye and resolution of previously seen enhancement on MRI. The patient is in remission with no further deterioration of his vision. Conclusion: This is the first reported case of isolated optic nerve involvement with a durable response to chemotherapy. This case emphasizes the importance of considering malignancy and maintaining a low threshold for optic nerve biopsy in patients with atypical cases of severe steroid-refractory vision loss with enhancement or enlargement of the optic nerve on MRI. Standard chemotherapy regimens for PCNSL can potentially achieve a curative response in these patients.
Highlights of ophthalmological manifestations in newly diagnosed acute leukemia: a correlation with hematological parameters

Dina N Laimon,Doaa H Sakr,Basma Atef,Yasmine Shaaban

DOI: https://doi.org/10.1007/s00277-024-05861-2

Abstract:Acute leukemia is a hematological malignancy affecting different organ systems including the eye and orbit through direct infiltration of tissues or secondary to hematological abnormalities. Ophthalmological manifestations in acute leukemia are variable ranging from asymptomatic presentation to serious manifestations that can alter the disease course and treatment. The purpose of this study is to detect the incidence of different ophthalmological manifestations in newly diagnosed acute leukemia patients and to assess the relationship between ocular findings and hematological characteristics and the sequel of these neoplasms. A cross-sectional study with analytical components was conducted on 222 newly diagnosed acute myeloid and acute lymphoblastic leukemia patients who presented at Oncology Center Mansoura University (OCMU) between January 2022 and February 2023. All patients underwent a complete ophthalmic evaluation at Mansoura Ophthalmology Center (MOC). The mean age was 43.45 ± 17.35 years (range, 17-85), and M/F was 137 (61.7%)/85 (38.3%). One-hundred and forty-four (64.9%) had acute myeloid leukemia (AML), and 78 (35.1%) had acute lymphoblastic leukemia (ALL). Ophthalmic manifestations were detected in 96 patients (43.2%). Among them, 4 (1.8%) had poor visual acuity. Retinal hemorrhage (19.8%) and Roth spots (17.1%) were the most common ocular manifestations. Other ophthalmological manifestations observed were orbital involvement (3.2%), ocular motility issues (1.4%), subconjunctival hemorrhage (5.9%), conjunctival chemosis (0.9%),lid swelling (4.1%), lid ecchymosis (3.2%), lagophthalmos (0.5%), lid ptosis (1.8%), retinal venous congestion & tortuosity (4.1%), preretinal hemorrhage (3.2%), vitreous hemorrhage (3.2%), macular affection (2.3%), retinal infiltration (1.8%), exudative retinal detachment (ERD) (1.8%), cotton-wool spots (0.9%), retinal vein occlusion (0.5%), papilledema (2.8%), optic disc infiltration (1.8%), disc pallor (1.8%).AML patients were significantly associated with a higher frequency of ocular affection, retinal hemorrhages, and Roth spots (P 0.028, 0.003, and 0.046, respectively) compared to ALL patients. Retinal hemorrhage was statistically significantly associated with anemia (P 0.021). Ophthalmological manifestations of acute leukemia are heterogeneous; they can be detected at initial presentations or relapse. Some manifestations are asymptomatic, others can affect visual acuity or even alter the disease course. Cooperation between ophthalmologists and haemato-oncologists is crucial for recognizing ocular involvement and disease management.
Predicting relapse in acute lymphoblastic leukemia

Marc S. Schwartz,Lori S. Muffly

DOI: https://doi.org/10.1080/10428194.2024.2387728

2024-09-03

Leukemia & Lymphoma

Abstract:Outcomes in adult and pediatric patients with acute lymphoblastic leukemia (ALL) have improved over successive generations due to rigorously conducted clinical trials and incorporation of novel therapeutic agents. Despite these advances, approximately 20% of high-risk pediatric patients and 50% of adults with ALL will fail to achieve long-term remission with frontline chemotherapy protocols, mostly due to relapse. The ability to predict which patients with ALL are more likely to relapse allows for early intensification of therapy and/or incorporation of novel immunotherapies with the goal of relapse prevention. In this review, we outline the most robust clinical predictors of relapse in ALL with a focus on measurable residual disease (MRD) and genomics. We also discuss application of these prognostic tools in different clinical settings including frontline treatment, pre-/post-allogeneic stem cell transplant, and pre-/post-Chimeric Antigen Receptor T-cell therapy.

oncology,hematology
Isolated Primary Central Nervous System Lymphoma of the Optic Nerve

Keertana Jain,Nicholas J. Volpe,Karan Dixit

DOI: https://doi.org/10.1097/nrl.0000000000000581

2024-09-27

The Neurologist

Abstract:Introduction: Optic nerve involvement in primary central nervous system lymphoma (PCNSL) has been reported only a few times in the literature, with generally dismal outcomes. We focused on an extremely rare presentation of PCNSL in an immunocompetent patient with isolated manifestations of the optic nerve. Case Report: A 72-year-old man presented with subacute vision loss in his left eye and optic disc swelling. Initial magnetic resonance imaging (MRI) of the orbits revealed a T2 hyperintense signal with enhancement of the left prechiasmatic optic nerve, suggestive of optic neuritis. He experienced visual improvement after 6 weeks of prednisone. However, 2 months after steroid tapering, he presented with worsening left-eye vision loss and new right-eye vision loss with imaging showing a peripherally enhancing chiasm lesion. A biopsy of the left optic nerve confirmed diffuse large B-cell lymphoma and negative systemic imaging was consistent with PCNSL. He was treated with high-dose methotrexate, rituximab, procarbazine vincristine (R-MVP), and cytarabine (AraC) with some visual improvement in the right eye and resolution of previously seen enhancement on MRI. The patient is in remission with no further deterioration of his vision. Conclusion: This is the first reported case of isolated optic nerve involvement with a durable response to chemotherapy. This case emphasizes the importance of considering malignancy and maintaining a low threshold for optic nerve biopsy in patients with atypical cases of severe steroid-refractory vision loss with enhancement or enlargement of the optic nerve on MRI. Standard chemotherapy regimens for PCNSL can potentially achieve a curative response in these patients.

clinical neurology
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

Catherine Thieblemont,Bettina Altmann,Fabian Frontzek,Loïc Renaud,Loic Chartier,Nicolas Ketterer,Christian Récher,Viola Poeschel,Olivier Fitoussi,Gerhard Held,Olivier Casasnovas,Corinne Haioun,Franck Morschhauser,Bertram Glass,Nicolas Mounier,Herve Tilly,Andreas Rosenwald,German Ott,Georg Lenz,Thierry Molina,Marita Ziepert,Norbert Schmitz

DOI: https://doi.org/10.1182/bloodadvances.2022008888

2023-08-08

Abstract:Most patients with diffuse large B-cell lymphoma (DLBCL) can be cured with immunochemotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients with progression or relapse in the central nervous system (CNS) face dismal outcomes. The impact of more aggressive regimens used in frontline therapy has not been systematically investigated in this context. To this end, we analyzed a large cohort of 2203 younger patients with DLBCL treated on 10 German (German Lymphoma Alliance [GLA]/The German High Grade Non-Hodgkin's Lymphoma Study Group [DSHNHL]) and French (The Lymphoma Study Association [LYSA]) prospective phase 2 and 3 trials after first-line therapy with R-CHOP, R-CHOEP (R-CHOP + etoposide), dose-escalated R-CHOEP followed by repetitive stem cell transplantation (R-MegaCHOEP), or R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycine, and prednisone) followed by consolidation including multiple drugs crossing the blood-brain barrier (BBB). Patients with DLBCL with an age-adjusted International Prognostic Index (aaIPI) of 0 to 1 showed very low cumulative incidence rates of CNS relapse regardless of first-line therapy and CNS prophylaxis (3-year cumulative incidences 0%-1%). Younger high-risk patients with aaIPI of 2 to 3 had 3-year cumulative incidence rates of 1.6% and 4% after R-ACVBP plus consolidation or R-(Mega)CHO(E)P, respectively (hazard ratio 2.4; 95% confidence interval: 0.8-7.4; P = .118). Thus, for younger high-risk patients, frontline regimens incorporating agents crossing the BBB may reduce often fatal CNS relapse.
How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia

Noam E Kopmar,Ryan D Cassaday

DOI: https://doi.org/10.1182/blood.2022017035

IF: 20.3

2023-03-23

Blood

Abstract:The central nervous system (CNS) is the most important site of extramedullary disease in adults with acute lymphoblastic leukemia (ALL). Although CNS disease is identified only in a minority of patients at the time of diagnosis, subsequent CNS relapses (either isolated or concurrent with other sites) occur in some patients even after the delivery of prophylactic therapy targeted to the CNS. Historically, prophylaxis against CNS disease has included intrathecal (IT) chemotherapy and radiotherapy (RT), although the latter is being used with decreasing frequency. Treatment of a CNS relapse usually involves intensive systemic therapy and cranial or craniospinal RT along with IT therapy and consideration of allogeneic hematopoietic cell transplant. However, short- and long-term toxicities can make these interventions prohibitively risky, particularly for older adults. As new antibody-based immunotherapy agents have been approved for relapsed/refractory B-cell ALL, their use specifically for patients with CNS disease is an area of keen interest not only because of the potential for efficacy but also concerns of unique toxicity to the CNS. In this review, we discuss data-driven approaches for these common and challenging clinical scenarios as well as highlight how recent findings potentially support the use of novel immunotherapeutic strategies for CNS disease.
Isolated central nervous system relapse in two adolescents with primary mediastinal large B-cell lymphoma after treatment with R-DA-EPOCH

Cricket Gullickson,Leslie Kersun,Anne Reilly,Alix Seif,Leena Chehab

DOI: https://doi.org/10.1002/pbc.31065

Abstract:The addition of rituximab to standard regimens for primary mediastinal large B-cell lymphoma (PMBCL) has significantly improved overall survival. However, the optimal management of isolated central nervous system (CNS) relapse and role of CNS prophylaxis remains undefined. We present cases of two adolescents with PMBCL who developed isolated CNS relapses. While isolated CNS relapse may be managed with high-dose chemotherapy and autologous stem cell transplant with or without CNS radiotherapy, review of these cases and the literature highlight the need for further work to define risk factors for CNS relapse, and identify patients who may benefit from CNS prophylaxis.
Clinical study of central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation

Li Lailing,Wang Xingbing,Sun Zimin

DOI: https://doi.org/10.19405/j.cnki.issn1000-1492.2013.01.014

2013-01-01

Abstract:Objective To study central nervous system(CNS) relapse of leukemia after allogeneic hematopoietic stem cell transplantation(HSCT) in order to get the correlation factors and outcome.Methods We reviewed the data of 288 patients with leukemia(98ALL/85AML/6 mix-AL/99CML) who received allogeneic HSCT in our hospital and retrospectively analyzed the incidence,risk factors,treatment and outcome of patients with CNS relapse.Results Eight patients developed CNS relapse at 160.5(95～622) days after HSCT with a cumulative incidence of 2.78%.The cumulative incidences of CNS relapse in patients with and without a history of CNS involvement before HSCT were 13.04%and 1.89%,respectively.ALL were at higher risk for CNS relapse in patients without a history of CNS involvement before HSCT(ALL 2.50%,AML 2.47%,and CML-CP 0%).In addition,it could not show a beneficial effect of prophylactic intrathecal chemotherapy on the incidence of CNS relapse in patients without a history of CNS involvement before HSCT.Three of the eight patients were alive,and,the 2-year overall survival(OS) after CNS relapse was 50%.Conclusion CNS relapse is not uncommon after HSCT in patients with acute leukemia,especially with a history of CNS involvement before HSCT,and they have high mortality and poor prognosis.Early diagnosis and appropriate management are crucial to the improvement of clinical outcomes in these patients.
Retinal haemorrhages as initial manifestation of leukaemia: a photo essay

Abhishek Gupta,Richa Gupta,Prabhakar Singh,Prabrisha Banerjee,Sweksha Priya,Anusuya Ghosh,Smriti Agrawal,Sandhya Kumari,Koyel Chakraborty,Mahuya Chattopadhyay,Shivani Sinha

DOI: https://doi.org/10.1038/s41433-024-03473-8

IF: 4.4563

2024-11-13

Eye

Abstract:Eye, Published online: 12 November 2024; doi:10.1038/s41433-024-03473-8 Retinal haemorrhages as initial manifestation of leukaemia: a photo essay

ophthalmology
Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020

Kathryn R Tringale,Michael Scordo,Joachim Yahalom,Charlie White,Zhigang Zhang,Behroze Vachha,Gustav Cederquist,Lauren Schaff,Lisa DeAngelis,Christian Grommes,Brandon S Imber

DOI: https://doi.org/10.1093/neuonc/noae115

2024-11-04

Abstract:Background: Contemporary outcomes and relapse patterns in primary CNS lymphoma (PCNSL) are lacking. We analyzed factors associated with relapse in a large cohort with extensive follow-up. Methods: T1-post-contrast-enhancing disease was characterized in immunocompetent PCNSL (diffuse large B-cell) patients from 1983 to 2020. Patients were stratified by response to induction and consolidation (complete/unconfirmed [CR/CRu], partial, stable, progression [POD]). Refractory was POD during (or relapse ≤3 months of) induction. Initial relapse site was categorized as local (involving/adjacent to baseline), distant intraparenchymal, leptomeningeal, or other. Progression-free (PFS) and overall survival (OS) were assessed with proportional hazards. Cumulative incidence with competing risks was used to assess local relapse. Results: Median follow-up was 7.4 years (N = 559). Most (321, 57%) were recursive partitioning analysis class 2 (age ≥50, Karnosfky Performance Status [KPS] ≥70). Most had supratentorial (420, 81%), multifocal (274, 53%), bilateral (224, 43%), and deep structure involvement (314, 56%). Nearly all received methotrexate-based induction (532, 95%). There was no difference in PFS or OS from consolidation based on initial response to induction (CR/CRu vs PR) in patients who ultimately achieved a CR/CRu to consolidation. PFS at 1-, 5 years for 351 patients with CR/CRu to consolidation was 80% (95% confidence interval [95% CI]: 76%-84%) and 46% (95% CI: 41%-53%), respectively; 1-year cumulative incidence of local versus nonlocal relapse was 1.8% versus 15%, respectively. For 97 refractory patients, 1-year cumulative incidence of local versus nonlocal relapse was 57% versus 42%, respectively. Deep structure involvement (HR 1.89, 95% CI: 1.10%-3.27%) was associated with local relapse in refractory patients. Conclusions: We report the first comprehensive relapse patterns in a large PCNSL cohort. While relapses post-CR to consolidation are typically distant and unpredictable, refractory patients had a relatively high incidence of local relapse. These findings can help optimize multimodality therapy for this highest-risk population.
OUTER RETINOPATHY AND MICROANGIOPATHY IN ACUTE MYELOGENOUS LEUKEMIA

Charles G Miller,Alexander J Brucker,Linda M Perry,Benjamin J Kim,Mary Ellen Martin,Noelle V Frey,Tomas S Aleman

DOI: https://doi.org/10.1097/ICB.0000000000001294

2023-11-01

Abstract:Purpose: To describe a patient with acute myelogenous leukemia who presented with a recurrent, bilateral, outer retinopathy, before and after consolidative peripheral blood stem cell transplantation complicated by chronic graft-versus-host disease. Methods: This is a retrospective review of records from a 23-year-old woman with acute myelogenous leukemia who underwent comprehensive ophthalmic evaluations for over a year including chromatic perimetry and multifocal electroretinograms, imaging with spectral domain optical coherence tomography, near-infrared and short-wavelength fundus reflectance and autofluorescence, fluorescein and optical coherence tomography angiography. Results: The patient presented with recurrent, unilateral paracentral scotomas. There was localized loss of inner segment ellipsoid (EZ) and photoreceptor outer segment signals (IZ) in the pericentral retina of both eyes co-localizing with hyperreflective lesions on near-infrared reflectance. She subsequently lost vision (visual acuity = 20/200) in the right eye a year after consolidative peripheral blood stem cell transplantation complicated by steroid-resistant-chronic graft-versus-host disease. There was loss of the EZ and IZ signals corresponding to a dense central cone scotoma and multifocal electroretinograms depression. Near-infrared autofluorescence, fluorescein and optical coherence tomography angiography were within normal limits. Visual acuity (20/20) and retinal sensitivities improved with restoration of the EZ/IZ signals after oral prednisone and intravenous rituximab, but left a residual photoreceptor loss and paracentral scotoma. Conclusion: We propose that an immune-mediated microangiopathy may explain the protracted, recurrent course of primary photoreceptor abnormalities in our patient, which was further complicated by manifestations of chronic graft-versus-host disease following consolidative peripheral blood stem cell transplantation. Outer retinal findings previously documented in leukemia may be explained by a similar mechanism.
Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

J Dufour,S Choquet,K Hoang-Xuan,A Schmitt,G Ahle,R Houot,L Taillandier,R Gressin,O Casasnovas,J P Marolleau,J Tamburini,C Serrier,E Perez,J Paillassa,E Gyan,A Chauchet,R Ursu,A Kas,C Soussain,C Houillier

DOI: https://doi.org/10.1007/s00277-023-05108-6

Abstract:Primary central nervous system lymphomas (PCNSLs) classically remain confined within the CNS throughout their evolution for unknown reasons. Our objective was to analyse the rare extracerebral relapses of PCNSL in a nationwide population-based study. We retrospectively selected PCNSL patients who experienced extracerebral relapse during their follow-up from the French LOC database. Of the 1968 PCNSL included in the database from 2011, 30 (1.5%, median age 71 years, median KPS 70) presented an extracerebral relapse, either pure (n = 20) or mixed (both extracerebral and in the CNS) (n = 10), with a histological confirmation in 20 cases. The median delay between initial diagnosis and systemic relapse was 15.5 months [2-121 months]. We found visceral (n = 23, 77%), including testis in 5 (28%) men and breast in 3 (27%) women, lymph node (n = 12, 40%), and peripheral nervous system (PNS) (n = 7, 23%) involvement. Twenty-seven patients were treated with chemotherapy, either with only systemic targets (n = 7) or mixed systemic and CNS targets (n = 20), 4 were consolidated by HCT-ASCT. After systemic relapse, the median progression-free survival and overall survival (OS) were 7 and 12 months, respectively. KPS > 70 and pure systemic relapses were significantly associated with higher OS. Extracerebral PCNSL relapses are rare, mainly extranodal, and frequently involve the testis, breast, and PNS. The prognosis was worse in mixed relapses. Early relapses raise the question of misdiagnosed occult extracerebral lymphoma at diagnostic workup that should systematically include a PET-CT. Paired tumour analysis at diagnosis/relapse would provide a better understanding of the underlying molecular mechanisms.
Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what's next?

Teena Bhatla,Stacy Cooper,Laura E. Hogan

DOI: https://doi.org/10.1080/10428194.2024.2362408

2024-06-12

Leukemia & Lymphoma

Abstract:While outcomes for newly diagnosed children with acute lymphoblastic leukemia (ALL) have improved over the last few decades, 10–15% will relapse. Outcomes for those children with relapse remains a challenge, with 5-year overall survival of approximately 35–60%. Large cooperative group trials have identified factors associated with favorable (low risk, LR) outcome at relapse, including later relapse, B-cell phenotype, isolated extramedullary relapse and a good response to initial re-induction therapy. Contemporary therapeutic regimens are aimed at improving outcomes, while decreasing toxicity. A main focus of current research involves how immunotherapy can be best incorporated with cytotoxic chemotherapy to improve survival in relapsed ALL. Here we review therapeutic strategies for LR relapse, including review of recently completed and ongoing trials.

oncology,hematology

Optic nerve head: an initial site of relapse in acute lymphoblastic leukaemia

Isolated Optic Nerve Relapse in a Pediatric Patient With T-Cell Lymphoblastic Leukemia: A Brief Report

Lymphopenia During Routine Follow-Up May Predict Relapse in Patients with Extranodal NK/T Cell Lymphoma

Leukaemic Optic Neuropathy in a Patient with Treated Acute Lymphoblastic Leukaemia: Optical Coherence Tomography as an Aid to Diagnosis

Bilateral optic nerve infiltration and leukemic retinopathy as initial signs of leukemia relapse with central nervous system involvement in an adult: a case report

Leukemic occult infiltrative optic neuropathy presenting as optic neuritis: a case report

A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings

Unilateral isolated optic nerve infiltration combined with central retinal artery occlusion in a patient with acute myeloid leukemia

Isolated Primary Central Nervous System Lymphoma of the Optic Nerve: A Case Report and Review of the Literature

Highlights of ophthalmological manifestations in newly diagnosed acute leukemia: a correlation with hematological parameters

Predicting relapse in acute lymphoblastic leukemia

Isolated Primary Central Nervous System Lymphoma of the Optic Nerve

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia

Isolated central nervous system relapse in two adolescents with primary mediastinal large B-cell lymphoma after treatment with R-DA-EPOCH

Clinical study of central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation

Retinal haemorrhages as initial manifestation of leukaemia: a photo essay

Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020

OUTER RETINOPATHY AND MICROANGIOPATHY IN ACUTE MYELOGENOUS LEUKEMIA

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what's next?